Insider Selling: Denali Therapeutics Inc (DNLI) Insider Sells 18,333 Shares of Stock

Denali Therapeutics Inc (NASDAQ:DNLI) insider Ryan J. Watts sold 18,333 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $25.03, for a total value of $458,874.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Denali Therapeutics stock traded up $0.44 during mid-day trading on Friday, hitting $24.71. The company’s stock had a trading volume of 276,708 shares, compared to its average volume of 394,825. The firm has a market capitalization of $2.32 billion, a price-to-earnings ratio of -63.36 and a beta of 2.11. Denali Therapeutics Inc has a 1 year low of $12.32 and a 1 year high of $28.86.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Tuesday, March 12th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.90. The company had revenue of $125.68 million during the quarter, compared to analyst estimates of $9.73 million. Denali Therapeutics had a negative return on equity of 7.12% and a negative net margin of 28.06%. Equities research analysts predict that Denali Therapeutics Inc will post -1.69 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the stock. Baillie Gifford & Co. grew its position in Denali Therapeutics by 13.5% in the fourth quarter. Baillie Gifford & Co. now owns 6,227,724 shares of the company’s stock worth $128,665,000 after acquiring an additional 741,303 shares during the period. Vanguard Group Inc lifted its stake in Denali Therapeutics by 52.5% during the third quarter. Vanguard Group Inc now owns 4,827,710 shares of the company’s stock worth $104,954,000 after purchasing an additional 1,660,984 shares in the last quarter. Vanguard Group Inc. lifted its stake in Denali Therapeutics by 52.5% during the third quarter. Vanguard Group Inc. now owns 4,827,710 shares of the company’s stock worth $104,954,000 after purchasing an additional 1,660,984 shares in the last quarter. BlackRock Inc. lifted its stake in Denali Therapeutics by 38.3% during the fourth quarter. BlackRock Inc. now owns 4,572,695 shares of the company’s stock worth $94,469,000 after purchasing an additional 1,265,645 shares in the last quarter. Finally, Lord Abbett & CO. LLC lifted its stake in Denali Therapeutics by 27.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,438,608 shares of the company’s stock worth $29,722,000 after purchasing an additional 313,153 shares in the last quarter. Institutional investors own 71.47% of the company’s stock.

A number of equities research analysts have recently issued reports on DNLI shares. Zacks Investment Research upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research report on Tuesday, April 9th. ValuEngine lowered Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 20th.

WARNING: “Insider Selling: Denali Therapeutics Inc (DNLI) Insider Sells 18,333 Shares of Stock” was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/denali-therapeutics-inc-dnli-insider-ryan-j-watts-sells-18333-shares-of-stock.html.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

See Also: Investing strategies using the yield curve

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.